Clinical considerations of the safety and efficacy of clofazimine in the treatment of nontuberculous mycobacterial disease

IF 1.5 4区医学 Q3 INFECTIOUS DISEASES

Journal of Infection and Chemotherapy Pub Date : 2025-09-30 DOI:10.1016/j.jiac.2025.102823

Fumiya Watanabe

引用次数: 0

Abstract

Clofazimine (CFZ) has been shown to exhibit synergism with amikacin and clarithromycin against nontuberculous mycobacteria (NTM), and is thus being repositioned to treat associated infections. However, clinical evidence supporting its efficacy and optimal dosage remains limited. Nonetheless, in vitro and retrospective studies have suggested its potential utility in treating NTM pulmonary disease. Moreover, CFZ pharmacokinetics and CFZ-induced side effects, such as pigmentation, heart rate corrected QT interval prolongation, and gastrointestinal disorders, are well characterized. This study aims to outline the pharmacokinetics of CFZ, as well as its efficacy and side effects, to inform its optimal use in the treatment of NTM pulmonary disease.

查看原文本刊更多论文

氯法齐明治疗非结核性分枝杆菌病的安全性和有效性的临床考虑。

氯法齐明（CFZ）已被证明与阿米卡星和克拉霉素对非结核分枝杆菌（NTM）具有协同作用，因此被重新定位用于治疗相关感染。然而，支持其疗效和最佳剂量的临床证据仍然有限。尽管如此，体外和回顾性研究表明其在治疗NTM肺部疾病中的潜在效用。此外，CFZ的药代动力学和CFZ引起的副作用，如色素沉积、心率校正的QT间期延长和胃肠道疾病，都得到了很好的表征。本研究旨在概述CFZ的药代动力学，以及其疗效和副作用，以告知其在NTM肺部疾病治疗中的最佳应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection and Chemotherapy INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY

CiteScore

4.10

自引率

4.50%

发文量

303

审稿时长

47 days

期刊介绍： The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.